• George M. Rodgers*
  • George M. Rodgers
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Anemia management is an important aspect of comprehensive care of the cancer patient. Many cancer patients receive suboptimal care in terms of anemia treatment. These patients should have an initial laboratory evaluation to exclude conditions such as iron or vitamin deficiency, and hemolysis. If these diagnoses are excluded, a diagnosis of anemia of cancer or chemotherapy is suggested. This condition results in functional iron deficiency and erythropoietin deficiency, and can be treated successfully in most patients with erythropoietic drugs and parenteral iron. This chapter summarizes appropriate use of these drugs and reviews their recommended doses, benefits, and risks.


Erythropoietin Darbepoetin Epoetin Parenteral iron Anemia Chemotherapy 


  1. 1.
    Tchekmedyian NS. 2002; Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology 16(9 Suppl 10):17–24.PubMedGoogle Scholar
  2. 2.
    Rodgers GM, Becker PS, Bennett CL,. et al. 2008; Cancer- and treatment-related anemia. J Natl Compr Canc Netw 6:536–64.PubMedGoogle Scholar
  3. 3.
    Curt GA, Breitbart W, Cella D,. et al. 2000; Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5:353–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Littlewood TJ, Bajetta E, Nortier JW,. et al. 2001; Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865–74.PubMedGoogle Scholar
  5. 5.
    Vansteenkiste J, Pirker R, Massuti B,. et al. 2002; Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211–20.PubMedCrossRefGoogle Scholar
  6. 6.
    Crawford J, Cella D, Cleeland CS,. et al. 2002; Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95:888–95.PubMedCrossRefGoogle Scholar
  7. 7.
    Rodgers GM. 2006; Guidelines for the use of erythropoietic growth factors in patients with chemotherapy-induced anemia. Oncology 20(Suppl 6):12–15.PubMedGoogle Scholar
  8. 8.
    Canon JL, Vansteenkiste J, Bodoky G,. et al. 2006; Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 98:273–84.PubMedCrossRefGoogle Scholar
  9. 9.
    Thames WASmith, SLScheifele, et al. AC2004; Evaluation of the US Oncology Network’s recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naive patients and patients switched from epoetin alfa Pharmacotherapy 24:313–23.PubMedCrossRefGoogle Scholar
  10. 10.
    Henry DH, Gordan LN, Charu V,. et al. 2006; Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia. Curr Med Res Opin 22:1403–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Patton J, Kuzur M, Liggett W,. et al. 2004; Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Oncologist 9:90–6. Erratum in: Oncologist 2004;9:240.PubMedCrossRefGoogle Scholar
  12. 12.
    Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008;111:25–41.PubMedCrossRefGoogle Scholar
  13. 13.
    Lyman GH, Glaspy J. 2006; Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer 106:223–33.PubMedCrossRefGoogle Scholar
  14. 14.
    Auerbach M, Barker L, Bahrain H,. et al. 2001; Intravenous iron optimizes the response to erythropoietin in patients with anemia of cancer and chemotherapy: results of a multicenter, open-label, randomized trial. Blood 98:799a (abstract).Google Scholar
  15. 15.
    Glaspy J, Vadhan-Raj S, Patel R,. et al. 2006; Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 24:2290–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Schwartzberg LS, Yee LK, Senecal FM,. et al. 2004; A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 9:696–707.PubMedCrossRefGoogle Scholar
  17. 17.
    Senecal FM, Yee, LGabrail, N. et al. 2005; Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Clin Breast Cancer 6:446–54.PubMedCrossRefGoogle Scholar
  18. 18.
    Waltzman R, Croot C, Justice GR,. et al. 2005; Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 10:642–50.PubMedCrossRefGoogle Scholar
  19. 19.
    Ross SD, Allen IE, Henry DH,. et al. 2006; Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 28:801–31.PubMedCrossRefGoogle Scholar
  20. 20.
    Cersosimo RJ, Jacobson DR. E2006; poetin alfa versus darbepoetin alfa in chemotherapy-related anemia. Ann Pharmacother 40:58–65.PubMedGoogle Scholar
  21. 21.
    Leyland-Jones B, Semiglazov V, Pawlicki M,. et al. 2005; Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23:5960–72.PubMedCrossRefGoogle Scholar
  22. 22.
    Henke M, Laszig R, Rube C,. et al. 2003; Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255–60.PubMedCrossRefGoogle Scholar
  23. 23.
    Glaspy JA. 2005; Cancer patient survival and erythropoietin. J Natl Compr Canc Netw 3:796–804.PubMedGoogle Scholar
  24. 24.
    Bohlius J, Wilson J, Seidenfeld J,. et al. 2006; Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 3:CD003407.PubMedGoogle Scholar
  25. 25.
    Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914–24.PubMedCrossRefGoogle Scholar
  26. 26.
    Crawford J. Erythropoiesis-stimulating protein support and survival. Oncology 2006;20(Suppl 6):39–43.PubMedGoogle Scholar
  27. 27.
    Glaspy JA. Erythropoiesis-Stimulating Agents in Oncology. J Natl Compr Canc Netw 2008;6:565–575.PubMedGoogle Scholar
  28. 28.
    Steensma DP, Loprinzi CL. 2006; Epoetin alfa and darbepoetin alfa go head to head. J Clin Oncol 24:2233–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Fishbane S, Frei GL, Maesaka J. 1995; Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Auerbach M, Ballard H, Trout JR,. et al. 2004; Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22:1301–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. 2004; On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 19:1571–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Laman CA, Silverstein SB, Rodgers GM. 2005; Parenteral iron therapy: a single institution’s experience over a 5-year period.J Natl Compr Canc Netw 3:791–5.PubMedGoogle Scholar
  33. 33.
    Silverstein SB, Rodgers GM. 2004; Parenteral iron therapy options. Am J Hematol 76:74–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. 2006; Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 21:378–82.PubMedCrossRefGoogle Scholar
  35. 35.
    Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231–42.PubMedCrossRefGoogle Scholar
  36. 36.
    Hedenus M, Birgegård G, Näsman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21:627–32.PubMedGoogle Scholar
  37. 37.
    Stead RB, Lambert J, Wessels D,. et al. 2006; Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 108:1830–4.PubMedCrossRefGoogle Scholar
  38. 38.
    Macdougall IC, Eckardt KU. 2006; Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia Lancet 368:947–53.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • George M. Rodgers*
    • 1
  • George M. Rodgers
    • 1
  1. 1.Huntsman Cancer InstituteUniversity of Utah Health Sciences CenterSalt Lake CityUSA

Personalised recommendations